Introduction: Colonization with Group B Streptococcus in pregnancy is a major risk factor for neonatal infection. Universal screening for maternal streptococcal colonization and the use of intrapartum antibiotic prophylaxis has resulted in substantial reductions of neonatal early-onset Group B Streptococcus disease. To achieve the best neonatal outcomes, it is imperative for maternity healthcare providers to adhere to screening and management guidelines.
Aim: This literature review uses a systematic approach and aims to provide a synthesis of what is known about compliance with Group B Streptococcus screening protocols in a variety of global settings, including maternity homes, private obstetric practice, and hospital clinical environments.
Methods: The review was carried out using electronic databases as well as hand-searching of reference lists. Included papers reported primarily on compliance with Group B Streptococcus screening guidelines, potential factors which influence compliance rates, and implementations and outcomes of interventions.
Results: Six international studies have been retained which all focused on adherence to Group B Streptococcus screening guidelines and demonstrated that different factors might have an influence on adherence to GBS screening protocols such as financial aspects and high caesarean section rates. Findings of relatively low compliance rates led to recognizing the need of developing improved strategies for optimising antenatal GBS screening adherence.
Conclusion: Adhering to Group B Streptococcus screening guidelines to prevent neonatal infection is crucial. Various factors influence compliance rates such as financial aspects and high proportions of caesarean sections. The implementation of strategies and different forms of education can result in improved compliance rates.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10995-020-03113-z | DOI Listing |
Proc Natl Acad Sci U S A
March 2025
Department of Biomedical Engineering, and Center for Advanced Genomic Technologies, Duke University, Durham, NC 27708.
CRISPR-Cas9 systems have revolutionized biotechnology, creating diverse new opportunities for biomedical research and therapeutic genome and epigenome editing. Despite the abundance of bacterial CRISPR-Cas9 systems, relatively few are effective in human cells, limiting the overall potential of CRISPR technology. To expand the CRISPR-Cas toolbox, we characterized a set of type II CRISPR-Cas9 systems from select bacterial genera and species encoding diverse Cas9s.
View Article and Find Full Text PDFDent Med Probl
March 2025
Department of Periodontal Diseases and Oral Mucosa Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Background: Chlorhexidine digluconate (CHG) is considered the most effective and safe antimicrobial agent in dentistry. Recently, it has often been produced in the form of preparations with additional substances that may modify its effect.
Objectives: The aim of the present study was to compare the efficacy of various simple and combined CHG rinses against selected bacterial and yeast strains.
Chemistry
March 2025
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Department of Molecular Pharmacology, 555 Zuchiongzhi Road, 201203, Shanghai, CHINA.
Sortase A (SrtA), a cysteine transpeptidase critical for surface protein anchoring in Gram-positive pathogens, represents an attractive antivirulence target. While covalent SrtA inhibitors show therapeutic potential, existing compounds lack species selectivity. Through structure-guided design, we developed T10, a covalent inhibitor selectively targeting Streptococcus pyogenes SrtA (SpSrtA) over Staphylococcus aureus SrtA (SaSrtA).
View Article and Find Full Text PDFJ Antimicrob Chemother
March 2025
Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Background: Acute sore throat is managed in community pharmacies in England and Wales under different clinical pathways: Acute Sore Throat Pharmacy First (ASTPF) and Sore Throat Test and Treat (STTT), respectively. ASTPF launched in 2024 and allows antibiotic supply with FeverPAIN scores 4 and 5. STTT launched in 2018 and allows antibiotic supply with FeverPAIN ≥2 or Centor ≥3, if point-of-care testing confirms presence of group A Streptococcus (GAS).
View Article and Find Full Text PDFInfez Med
March 2025
Microbiology Laboratory, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Aims: The aim of this study was to assess the possible use of time to positivity (TTP) of blood cultures (BCs) collected at the Emergency Department (ED) to estimate the probability of pyogenic streptococci versus other Gram positive cocci in pairs and chains, such as , other viridans group streptococci or enterococci.
Methods: All patients 18 years of age or older evaluated at the ED from whom BCs were collected and were positive for Gram positive cocci in pairs and chains at the microscopic examination, were included in the study. The BCs included were collected by venipuncture, were mono-microbial and were the first bottles that flagged positive in each set.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!